Nautilus Biotechnology Inc Total Assets
Nautilus Biotechnology Inc total assets. Based on the latest financial reports, Nautilus Biotechnology Inc (NAUT) holds total assets worth $163.58 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Nautilus Biotechnology Inc market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Nautilus Biotechnology Inc (2018–2025)
Total assets of Nautilus Biotechnology Inc from 2018 to 2025. This chart illustrates how Nautilus Biotechnology Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Nautilus Biotechnology Inc for real-time trading data and today's change.
Nautilus Biotechnology Inc - Asset Composition Analysis
Nautilus Biotechnology Inc Total Assets Breakdown (December 2025)
Nautilus Biotechnology Inc total assets breakdown as of December 2025. Nautilus Biotechnology Inc's total assets of $163.58 Million consist of 55.5% current assets and 44.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Nautilus Biotechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NAUT working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nautilus Biotechnology Inc's current assets represent 55.5% of total assets in 2025, an increase from 0.9% in 2018.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2025, up from 0.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Nautilus Biotechnology Inc Competitors by Total Assets
Key competitors of Nautilus Biotechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Nautilus Biotechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.14 | 18.52 | 83.68 |
| Quick Ratio | 10.14 | 18.52 | 83.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $78.99 Million | $142.59 Million | $348.01 Million |
Nautilus Biotechnology Inc - Advanced Valuation Insights
This section examines the relationship between Nautilus Biotechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.93 |
| Latest Market Cap to Assets Ratio | 1.21 |
| Asset Growth Rate (YoY) | -21.3% |
| Total Assets | $191.11 Million |
| Market Capitalization | $231.60 Million USD |
Valuation Analysis
Above Book Valuation: The market values Nautilus Biotechnology Inc's assets above their book value (1.21x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Nautilus Biotechnology Inc's assets decreased by 21.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nautilus Biotechnology Inc (2018–2025)
The table below shows the annual total assets of Nautilus Biotechnology Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $191.11 Million | -21.27% |
| 2024-12-31 | $242.74 Million | -20.56% |
| 2023-12-31 | $305.56 Million | -12.71% |
| 2022-12-31 | $350.05 Million | -12.15% |
| 2021-12-31 | $398.45 Million | +368.70% |
| 2020-12-31 | $85.01 Million | +358.48% |
| 2019-12-31 | $18.54 Million | -87.28% |
| 2018-12-31 | $145.82 Million | -- |
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument,… Read more